Navigation Links
New technique tracks proteins in single HIV particle
Date:5/5/2014

An interdisciplinary team of scientists from KU Leuven in Belgium has developed a new technique to examine how proteins interact with each other at the level of a single HIV viral particle. The technique allows scientists to study the life-threatening virus in detail and makes screening potential anti-HIV drugs quicker and more efficient. The technique can also be used to study other diseases.

Understanding how the human immunodeficiency virus (HIV) reproduces itself is crucial in the effort to fight the disease. Upon entering the bloodstream, HIV viral particles, or virions, 'highjack' individual immune cells. The virion binds to and then penetrates the immune cell. Once inside, the virion reprograms the genetic material of the immune cell to produce more HIV virions. In this way, HIV disables the disease-fighting 'bodyguards' in our blood and turns them into breeding machines for new HIV virions.

Integrase plays a key role throughout this whole process: "Integrase is the HIV protein that causes the genetic material of HIV to link to that of the hijacked cell. It ensures the programming of the human cell upon infection. In our study, we wanted to track integrase during the different stages of infection," explains postdoctoral researcher Jelle Hendrix (Department of Chemistry). The challenge is to do this at the level of a single virion: "HIV has multiple ways of doing the same thing. This is the case for cell penetration, for instance. So it is certainly useful to be able to see exactly how the individual HIV virions are behaving."

To achieve this, the researchers used single-molecule fluorescence imaging. They engineered a genetically modified HIV virion that was capable of infecting the cell but incapable of reproducing inside it. The virion was programmed to produce a fluorescent form of integrase. "This allowed us to examine the interactions of the florescent integrase under the light microscope both in vitro in a single HIV virion as well as in a human cell infected with it."

"We then used the technique to study both clinically approved and newly developed HIV inhibitors. Some of these drugs were thought to affect interaction between integrase particles. With our new technique, we were able to observe that this was indeed the case."

"There are already a few dozen medications available for HIV, but further research is essential. Whenever HIV multiplies by hijacking an immune cell, there is a chance of mutation, and there is no guarantee that an HIV drug will be able to handle that mutation. A medication may not be as effective over the course of a patient's lifetime. Moreover, current HIV drugs are very expensive. Hence the importance of being able to test anti-HIV medications quickly and efficiently."

The good news is that this new technique can be broadly applied: "It may seem surprising, but we can also use a genetically modified version of a dangerous virus to examine other pathogens. Essentially, we have created a nano test tube out of an HIV virion, inside of which protein interactions can be studied. In principle, we can make any protein fluorescent, be it from HIV, from another disease or from a human cell."

"Researchers have been studying protein interactions for some time, but studying them at the level of a single viral particle was not possible until now," says Jelle Hendrix. Our technique allows scientists to quickly test many molecules potential medications for many diseases using minimal material. In future research, we will be using the technique to study integrase proteins of other viruses."


'/>"/>

Contact: Dr. Jelle Hendrix
jelle.hendrix@chem.kuleuven.be
32-016-327-344
KU Leuven
Source:Eurekalert

Related biology news :

1. Ground breaking technique offers DNA Sat Nav direct to your ancestors home 1,000 years ago
2. New technique detects microscopic diabetes-related eye damage
3. New technique will accelerate genetic characterization of photosynthesis
4. New technique takes cues from astronomy and ophthalmology to sharpen microscope images
5. Researchers develop novel molecular blood group typing technique
6. New technique brings us closer to HIV and Hepatitis C vaccines
7. New technique sheds light on human neural networks
8. New technique for identifying gene-enhancers
9. Heat-based technique offers new way to measure microscopic particles
10. NIST microanalysis technique makes the most of small nanoparticle samples
11. New technique makes biogasoline from plant waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ... at the LEERINK Partners 6th Annual Global Healthcare Conference ... February 15, 2017 at 10 a.m. Eastern Time. ... be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... ... 2017 , ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, ... Health (NIMH) for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ... to deliver therapeutic levels of olanzapine for a period of 3 months., “We are ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... 23, 2017 China Biologic Products, Inc. (NASDAQ: CBPO) ... biopharmaceutical company in China, today announced its financial results for ... Fourth Quarter 2016 Financial Highlights ... 21.7% in RMB terms, or increased by 13.6% in USD ... quarter of 2015. Gross profit increased by ...
(Date:2/23/2017)... 23, 2017 ... per share data, unaudited)Three Months Ended December 31,Twelve Months ... $         ...   89026%Aldurazyme Net Product Revenue ... Net Product Revenue  756025%297303(2)%Vimizim Net ...
Breaking Biology Technology: